TAKARA BIO INC chart

Last update: 2021-02-19
Key statistics and financials
Revenue per share 552.50
Dividend & Yield66.00¥ (3.26%)
Beta 0.14
Market capitalization 234.93B
Operating cash flow 5.15B
ESG Scores unknown

Company description

Takara Bio Inc., together with its subsidiaries, operates as a biotechnology company in Japan, the United States, China, other Asia, Europe, and internationally. The company operates through Bioindustry and Gene Therapy segments. It develops research reagents and scientific instruments; and provides contract development and manufacturing organization (CDMO) services for academic and corporate life sciences research and development. The company's CDMO services include contract service for developing regenerative medicine products; related services, such as quality and safety testing, and cell banking; and contract services for supporting genetic analysis and testing comprising human genome sequence analysis, analysis of cancerrelated genes, and intestinal flora analysis, as well as support services for genetic engineering research, such as genome editing using the latest technologies and equipment. It also engages in the development and commercialization of various gene therapies, including oncolytic virus utilizing Canerpaturev, which is an attenuated strain of the herpes simplex virus type 1 that exhibits antitumor activity upon local injection into a tumor due to tumor lysis; siTCR gene therapy, which is in Phase I/II clinical trials for the treatment of synovial sarcoma; and CD19 chimeric antigen receptors that is in Phase I/II clinical trial for the treatment of adult acute lymphoblastic leukemia. Additionally, the company offers RetroNectin for gene therapy. The company was founded in 2002 and is headquartered in Kusatsu, Japan. Takara Bio Inc. is a subsidiary of Takara Holdings Inc.

Sector: Healthcare - Industry: Biotechnology

Financial data

Financial Statements

Cashflow Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Change To Liabilities -199M -468M 1.02B -431M
Total Cashflows From Investing Activities -5.58B -212M -3.78B -7.07B
Net Borrowings
Total Cash From Financing Activities -541M -946M -1.1B -2.07B
Change To Operating Activities 717M -265M 2.49B -316M
Issuance Of Stock
Net Income 3.66B 3.82B 9.55B 19.85B
Change In Cash -587M 5B 8.85B -1.15B
Effect Of Exchange Rate -252M -182M -215M 1.01B
Total Cash From Operating Activities 5.78B 6.34B 13.94B 6.99B
Depreciation 3.38B 3.53B 3.79B 4.15B
Change To Account Receivables -974M -579M -3.56B -4.81B
Other Cashflows From Financing Activities -105M -105M -141M -147M
Change To Netincome -423M -338M -1.58B -4.9B
Capital Expenditures -5.98B -3.98B -8.69B -12.4B

Income Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Research Development 4.34B 3.87B 5.54B 6.11B
Income Before Tax 4.82B 5.43B 13.55B 27.53B
Net Income 3.66B 3.82B 9.55B 19.85B
Selling General Administrative 10.88B 10.95B 12.36B 14.18B
Gross Profit 20.69B 21.11B 31.87B 49.21B
Ebit 5.46B 6.28B 13.95B 28.9B
Operating Income 5.46B 6.28B 13.95B 28.9B
Interest Expense -7M -7M -24M -23M
Income Tax Expense 1.15B 1.6B 3.97B 7.62B
Total Revenue 35.84B 34.56B 46.09B 67.7B
Cost Of Revenue 15.15B 13.46B 14.21B 18.49B
Total Other Income ExpenseNet -644M -845M -401M -1.37B
Net Income From Continuing Ops 3.67B 3.83B 9.58B 19.91B
Net Income Applicable To Common Shares 3.66B 3.82B 9.55B 19.85B

Balance Sheet Statement 2019-03-31 2020-03-31 2021-03-31 2022-03-31
Total Liabilities 6.95B 8.42B 15.45B 19.65B
Total Stockholder Equity 64.01B 66.5B 74.18B 95.87B
Other Current Liabilities 3.89B 4.53B 10.24B 14.36B
Total Assets 71.04B 75.01B 89.75B 115.71B
Common Stock 14.96B 14.96B 14.96B 14.96B
Other Current Assets 944M 1.48B 1.35B 2.64B
Retained Earnings 15.4B 18.5B 27.09B 45.01B
Treasury Stock 750M 136M -761M 3B
Cash 17.03B 18.27B 25.99B 23.63B
Total Current Liabilities 6.02B 6.25B 13.19B 17.38B
Other Stockholder Equity 750M 136M -761M 3B
Property, Plant, and Equipment 21.4B 24.21B 29.77B 36.4B
Total Current Assets 35.27B 38.39B 49.12B 68.14B
Net Tangible Assets 51.38B 55.14B 64.81B 86.71B
Net Receivables 8.56B 9.05B 12.59B 17.8B
Accounts Payable 1.54B 1.03B 2.08B 1.96B


Insider Transactions

Here are the insider transactions of stock shares related to TAKARA BIO INC:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to TAKARA BIO INC. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on TAKARA BIO INC

Here is the result of two systematic investment strategies applied to TAKARA BIO INC. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on TAKARA BIO INC

The following chart shows the equity curve of the two systematic investment strategies applied to TAKARA BIO INC:

TAKARA BIO INC automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 58.3% on the backtest period.

Performance at glance

Performance

58.3 %

Latent gain

8585.0 ¥

Invested capital

14725.0 ¥

Annualized return

13.88 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on TAKARA BIO INC

This is the result of two momentum investment strategies applied to TAKARA BIO INC. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on TAKARA BIO INC

The following chart shows all the entries opened by the momentum investment system on TAKARA BIO INC:

TAKARA BIO INC momentum entries
  • The first momentum investment strategy would give 121.63% of return on TAKARA BIO INC. That represents 10965.0¥ of latent gain with 9015.0¥ of employed capital.
  • The second momentum investment strategy would give 104.42% of return on TAKARA BIO INC. That represents 10206.0¥ of latent gain with 9774.0¥ of employed capital.
Performance at glance (1Q Momentum)

Performance

121.63 %

Latent gain

10965.0 ¥

Invested capital

9015.0 ¥

Annualized return

22.8 %
Performance at glance (2Q Momentum)

Performance

104.42 %

Latent gain

10206.0 ¥

Invested capital

9774.0 ¥

Annualized return

28.07 %

Momentum equity curve on TAKARA BIO INC

The following chart shows the equity curve of the two momentum strategies applied to TAKARA BIO INC:

TAKARA BIO INC momentum equity

Note: the dividends potentially given by TAKARA BIO INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TAKARA BIO INC

The following chart shows the employed capital evolution of the two momentum strategies on TAKARA BIO INC since the beginning:

TAKARA BIO INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250¥, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000¥.


Buy the dip strategy result on TAKARA BIO INC

Buy the dip entry openings on TAKARA BIO INC

TAKARA BIO INC

The performance achieved by the robo-advisor on TAKARA BIO INC is 50.15%. That represents 4449.0$ of latent gain with 8871.0¥ of employed capital. The following chart shows TAKARA BIO INC stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of TAKARA BIO INC, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

50.15 %

Latent gain

4449.0 ¥

Invested capital

8871.0 ¥

Annualized return

22.8 %

Equity curve of the strategy applied to TAKARA BIO INC

The following chart shows the result of the investment strategy applied to TAKARA BIO INC:

TAKARA BIO INC

Note: the dividends potentially given by TAKARA BIO INC are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on TAKARA BIO INC

The following chart shows the employed capital evolution since the beginning of the investment strategy on TAKARA BIO INC:

TAKARA BIO INC

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on TAKARA BIO INC

In this section, I will compare the three previous investment strategies applied to TAKARA BIO INC.

Equity curve comparison on TAKARA BIO INC

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

TAKARA BIO INC investment strategy comparison

Employed capital comparison on TAKARA BIO INC

TAKARA BIO INC investment comparison

Performance comparison on TAKARA BIO INC

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 58.3% 8585.0¥ 14725.0¥ 13.88%
Momentum 1 quarter 121.63% 10965.0¥ 9015.0¥ 30.71%
Momentum 2 quarters 104.42% 10206.0¥ 9774.0¥ 28.07%
Non-directional 50.15% 4449.0¥ 8871.0¥ 22.8%
Annualized return comparison

Automatic investment

13.88 %

Momentum 1Q

28.07 %

Momentum 2Q

28.07 %

Non-directional

22.8 %

Correlated stocks

Here are the most positively and negatively correlated stocks with TAKARA BIO INC:

Positive correlations

Most correlated stocks this year


Most correlated stocks last 3 months

Negative correlation

Most negatively correlated stocks this year


Most negatively correlated stocks last 3 months

Note: The algorithm computes the probability of correlation between TAKARA BIO INC and the other stocks. There may be false positives or some missing correlated stocks. If the price of TAKARA BIO INC does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name TAKARA BIO INC
Country Japan
City Kusatsu
Address 7-4-38 Nojihigashi
Phone 81 77 565 6920
Website www.takara-bio.com
FullTime employees 1666
Industry Biotechnology
Sector Healthcare
Exchange XTKS
Ticker 4974.XTKS
Market www.jpx.co.jp

TAKARA BIO INC ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown